Gallbladder Cancer: Current Multimodality Treatment Concepts and Future Directions
Open Access
Abstract
Gallbladder cancer (GBC) is the most common primary tumor site of biliary tract cancer (BTC), accounting for 0.6% of newly diagnosed cancers and 0.9% of cancer-related deaths. Risk factors, including female sex, age, ethnic background, and chronic inflammation of the gallbladder, have been identified. Surgery is the only curative option for early-stage GBC, but only 10% of patients are primary eligible for curative treatment. After neoadjuvant treatment, up to one-third of locally advanced GBC patients could benefit from secondary surgical treatment. After surgery, only a high-risk subset of patients benefits from adjuvant treatment. For advanced-stage GBC, palliative chemotherapy with gemcitabine and cisplatin is the current standard of care in line with other BTCs. After the failure of gemcitabine and cisplatin, data for second-line treatment in non-resectable GBC is poor, and the only recommended chemotherapy regimen is FOLFOX (5-FU/folinic acid and oxaliplatin). Recent advances with the PD-L1 inhibitor durvalumab open the therapy landscape for immune checkpoint inhibition in GBC. Meanwhile, targeted therapy approaches are a cornerstone of GBC therapy based on molecular profiling and new evidence of molecular differences between different BTC forms and might further improve the prognosis of GBC patients.Keywords
This publication has 170 references indexed in Scilit:
- Multi-Institutional Phase II Study of Selumetinib in Patients With Metastatic Biliary CancersJournal of Clinical Oncology, 2011
- A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma: Southwest Oncology Group study S0202Cancer Chemotherapy and Pharmacology, 2011
- Phase II trial of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehydethiosemicarbazone plus gemcitabine in patients with advanced biliary tract cancerCancer Chemotherapy and Pharmacology, 2010
- Gemcitabine with carboplatin for advanced biliary tract cancers: a phase II single institution studyHPB, 2010
- Report of a Multicenter Phase II Trial Testing a Combination of Biweekly Bevacizumab and Daily Erlotinib in Patients With Unresectable Biliary Cancer: A Phase II Consortium StudyJournal of Clinical Oncology, 2010
- Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in JapanBritish Journal of Cancer, 2010
- Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract CancerNew England Journal of Medicine, 2010
- Sorafenib in patients with advanced biliary tract carcinoma: a phase II trialBritish Journal of Cancer, 2009
- Epidemiology of biliary tract cancers: an updateAnnals of Oncology, 2008
- Phase II Study of Erlotinib in Patients With Advanced Biliary CancerJournal of Clinical Oncology, 2006